The proposal of the Association for Molecular Pathology Economic Affairs Committee details two schemes for coding genomic sequencing assays. Submitted in March to the AMA's CPT Editorial Panel.
The timely report provides a detailed and compelling overview of the landscape of next generation sequencing (NGS) technology and its clinical relevance and impact on improving patient care.
AMP v USPTO case challenges patents as dangerous roadblock to patient care, medical Innovation.
The Association for Molecular Pathology (AMP) announced a record-breaking number of abstract submissions for the AMP 2012 Annual Meeting on Genomic Medicine, marking a 40% increase over last year. The Meeting will be held October 25-27, 2012 in Long Beach, CA. An increase in the number of meeting attendees and exhibitors is anticipated as well.
The Association for Molecular Pathology (AMP) today announced that it is close to finalizing a framework proposal for CPT coding of Next Generation Sequencing (NGS) assays.
The Association for Molecular Pathology (AMP) today announced that it has formed a working group that will focus on the oversight of laboratory-developed tests (LDTs). In 2009, the U.S. Food and Drug Administration (FDA) announced an intention to abandon its regulatory policy of enforcement discretion toward some laboratory developed tests.
Now that the Supreme Court has remanded Association for Molecular Pathology et al. v. Myriad Genetics, Inc., et al. (AMP v. Myriad) to the Court of Appeals for the Federal Circuit for further consideration, AMP is optimistic that it will ultimately prevail in its lawsuit to invalidate patents on two genes that are known to cause breast cancer.
The Association for Molecular Pathology (AMP) applauds the U.S. Supreme Court’s ruling today in the case of Mayo Collaborative Services v. Prometheus Laboratories as a victory for patients and for the advancement of personalized medicine.
AMP presented testimony to the U.S. Patent and Trademark Office requesting moratorium on human gene patenting.
The Association for Molecular Pathology (AMP) adopts change in governance structure as part of newly implemented strategic plan.
The American Civil Liberties Union and the Public Patent Foundation have petitioned the U.S. Supreme Court to hear Association for Molecular Pathology v. U.S. Patent and Trademark Office, a case that challenges the validity of patents on two human genes associated with hereditary breast and ovarian cancer.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
The Association for Molecular Pathology (AMP) today announced the 2011 AMP Award winners during the Association’s Annual Meeting in Dallas.
The Association for Molecular Pathology (AMP) today announced the AMP Council’s unanimous approval of a strategic plan intended to guide the organization over the next four years.
The Association for Molecular Pathology (AMP) submitted comments to the National Institutes of Health (NIH), in which the Association voiced concerns about the proposed Genetic Testing Registry (GTR) as currently designed, and requested that NIH take clarity and cost into consideration when designing a test registry.
The Association for Molecular Pathology (AMP) submitted comments to the Food and Drug Administration (FDA) regarding the FDA’s “Draft Guidance for Industry and Food and Drug Administration Staff – In Vitro Companion Diagnostic Devices”.
The Association for Molecular Pathology (AMP) expresses concern that the proposed rule’s determination that biospecimens cannot be de-identified will limit validation of clinical tests.
The Association for Molecular Pathology (AMP) has announced the program of events for its Annual Meeting, being held November 17-19 at the Gaylord Texan Hotel and Convention Center in Grapevine, Texas.
The Association for Molecular Pathology (AMP) submitted comments to the US Food and Drug Administration on the draft guidance document titled, “Commercially Distributed In Vitro Diagnostic Products Labeled for Research Use Only or Investigational Use Only: Frequently Asked Questions.”
The Association for Molecular Pathology (AMP), an international medical professional association dedicated to the advancement, practice, and research of clinical molecular laboratory medicine, has retained Lambert, Edwards & Associates (LE&A) to provide public relations services for the Association and the rapidly growing field of molecular diagnostics.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right